March 2, 2018 / 10:18 AM / 3 months ago

BRIEF-Biogen And Abbvie Announce The Voluntary Worldwide Withdrawal Of Marketing Authorizations For Zinbryta

March 2 (Reuters) - Abbvie Inc:

* BIOGEN AND ABBVIE ANNOUNCE THE VOLUNTARY WORLDWIDE WITHDRAWAL OF MARKETING AUTHORIZATIONS FOR ZINBRYTA® (DACLIZUMAB) FOR RELAPSING MULTIPLE SCLEROSIS

* ABBVIE INC - EMA HAS INITIATED AN ARTICLE 20 REFERRAL PROCEDURE FOLLOWING REPORTS OF INFLAMMATORY ENCEPHALITIS AND MENINGOENCEPHALITIS

* ABBVIE - ‍BIOGEN WILL CONTINUE TO WORK WITH REGULATORY AUTHORITIES & WITH HEALTHCARE PROVIDERS IN THEIR MANAGEMENT OF ZINBRYTA PATIENTS​

* ABBVIE - GIVEN NATURE OF ADVERSE EVENTS REPORTED, CHARACTERIZING PROFILE OF ZINBRYTA TO NOT BE POSSIBLE GOING AHEAD WITH LIMITED PATIENTS BEING TREATED

* ABBVIE INC - BIOGEN BELIEVES VOLUNTARY WORLDWIDE WITHDRAWAL OF ZINBRYTA “IS IN BEST INTEREST OF PATIENTS” Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below